More recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established as a new class of glucose lowering agents which also reduce the incidence of DKD (Keri, Samji & Blumenthal, 2018). This evidence concerns the gene SLC5A2 and diabetic kidney disease.